Enhanced contact investigations for nine early travel-related cases of SARS-CoV-2 in the United States

Background Coronavirus disease 2019 (COVID-19), the respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in Wuhan, China and has since become pandemic. As part of initial response activities in the United States, enhanced contact investigations were conducted to enable early identification and isolation of additional cases and to learn more about risk factors for transmission. Methods Close contacts of nine early travel-related cases in the United States were identified. Close contacts meeting criteria for active monitoring were followed, and selected individuals were targeted for collection of additional exposure details and respiratory samples. Respiratory samples were tested for SARS-CoV-2 by real-time reverse transcription polymerase chain reaction (RT-PCR) at the Centers for Disease Control and Prevention. Results There were 404 close contacts who underwent active monitoring in the response jurisdictions; 338 had at least basic exposure data, of whom 159 had at least 1 set of respiratory samples collected and tested. Across all known close contacts under monitoring, two additional cases were identified; both secondary cases were in spouses of travel-associated case patients. The secondary attack rate among household members, all of whom had at least 1 respiratory sample tested, was 13% (95% CI: 4 - 38%). Conclusions The enhanced contact tracing investigations undertaken around nine early travel-related cases of COVID-19 in the United States identified two cases of secondary transmission, both spouses. Rapid detection and isolation of the travel-associated case patients, enabled by public awareness of COVID-19 among travelers from China, may have mitigated transmission risk among close contacts of these cases.

[1]  Melis N. Anahtar,et al.  Phylogenetic analysis of SARS-CoV-2 in the Boston area highlights the role of recurrent importation and superspreading events. , 2020, medRxiv.

[2]  K. Pettrone,et al.  Investigation and Serologic Follow-Up of Contacts of an Early Confirmed Case-Patient with COVID-19, Washington, USA , 2020, Emerging infectious diseases.

[3]  W. Wei,et al.  Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[4]  Trevor Bedford,et al.  Cryptic transmission of SARS-CoV-2 in Washington state , 2020, Science.

[5]  D. Lung,et al.  Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong , 2020, Journal of Hospital Infection.

[6]  Anne Kimball,et al.  Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[7]  Anna M. Acosta,et al.  Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[8]  Y. Choe Coronavirus Disease-19: Summary of 2,370 Contact Investigations of the First 30 Cases in the Republic of Korea , 2020, medRxiv.

[9]  Zheng Zhao,et al.  Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures , 2020, The Lancet.

[10]  H. Kirking,et al.  First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA , 2020, The Lancet.

[11]  Alicia M. Fry,et al.  Active Monitoring of Persons Exposed to Patients with Confirmed COVID-19 — United States, January–February 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[12]  O. Tsang,et al.  Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong , 2020, Infection Control & Hospital Epidemiology.

[13]  S. Blomqvist,et al.  Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  Yang Liu,et al.  Secondary attack rate and superspreading events for SARS-CoV-2 , 2020, The Lancet.

[15]  Anita Patel,et al.  Initial public health response and interim clinical guidance for the 2019 novel coronavirus outbreak — United States, December 31, 2019–February 4, 2020 , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  Yan Bai,et al.  Presumed Asymptomatic Carrier Transmission of COVID-19. , 2020, JAMA.

[17]  Lijuan Xiong,et al.  Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.

[18]  Wei Liu,et al.  Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China , 2020, medRxiv.

[19]  Dylan S. Small,et al.  Analysis of the epidemic growth of the early 2019-nCoV outbreak using internationally confirmed cases , 2020, medRxiv.

[20]  Michael Bell,et al.  Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak — United States, December 31, 2019–February 4, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[21]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[22]  Sunmi Kim,et al.  Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea , 2020, Osong public health and research perspectives.

[23]  C. Campèse,et al.  First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[24]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[25]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[26]  M. Baguelin,et al.  Report 3: Transmissibility of 2019-nCoV , 2020 .

[27]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[28]  Mary Johnson Wuhan 2019 Novel Coronavirus - 2019-nCoV , 2020 .

[29]  Estimation of the Time-Varying Reproduction Number of 2019-nCoV Outbreak in China , 2020 .

[30]  Sung-il Cho,et al.  Clinical and Epidemiologic Characteristics of Spreaders of Middle East Respiratory Syndrome Coronavirus during the 2015 Outbreak in Korea , 2017, Journal of Korean medical science.

[31]  D. Feikin,et al.  Middle East Respiratory Syndrome Coronavirus Transmission in Extended Family, Saudi Arabia, 2014 , 2016, Emerging infectious diseases.

[32]  A. Kallen,et al.  Transmission of Middle East Respiratory Syndrome Coronavirus Infections in Healthcare Settings, Abu Dhabi , 2016, Emerging infectious diseases.